Escitalopram Maintenance Treatment for Prevention of Recurrent Depression: A Randomized, Placebo-Controlled Trial
The DOI matches its Crossref record, with a small difference in title or year; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Major depressive disorder is a recurrent illness that often requires maintenance antidepressant treatment. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that has shown efficacy in both acute and continuation treatment of major depressive disorder. The current trial examined the efficacy of maintenance escitalopram treatment in preventing depression recurrence in patients who responded to acute SSRI therapy. METHOD: Patients with recurrent DSM-IV-defined major depressive disorder (>or= 2 previous episodes; baseline Montgomery-Asberg Depression Rating Scale [MADRS] score >or= 22) who had responded (MADRS score or= 22 or insufficient therapeutic response during the double-blind phase. The study was conducted between October 16, 2000, and February 4, 2003. RESULTS: A total of 234 patients who responded to acute open-label treatment with 1 of 4 SSRIs received at least 1 dose of open-label escitalopram continuation treatment. Of 164 patients who completed escitalopram continuation treatment, 139 were randomly assigned to double-blind maintenance treatment with escitalopram (N = 73) or placebo (N = 66). Mean baseline MADRS scores at the start of the maintenance phase were < 5 for both the placebo- and escitalopram-treatment groups. Time to recurrence was significantly longer in patients who received maintenance treatment with escitalopram compared with patients switched to placebo (hazard ratio = 0.26, 95% CI = 0.13 to 0.52, p < .001). Long-term escitalopram treatment was well tolerated. CONCLUSION: Maintenance treatment with escitalopram was well tolerated and significantly reduced the risk for recurrence of depression. Patients with few residual symptoms following continuation treatment with escitalopram experienced a high rate of depression recurrence when switched to placebo, demonstrating the need for maintenance therapy of recurrent major depressive disorder beyond 4 to 6 months of initial symptom resolution even if few residual symptoms are present.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kornstein 2006 (n = 139) reported one suicide attempt one month a er the last reported dose of blinded placebo in a participant with a history of suicide attempt in the discontinuation group (n = 66), and this was assessed by the investigator as 'possibly related' to study medication.However,”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Kornstein 2006
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
Three-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Recurrence after recovery from major depressive disorder during 15 years of observational follow-up
Mueller, T. I., Leon, A. C., Keller, M. B., Solomon, D. A., Endicott, J., Coryell, W., Warshaw, M., & Maser, J. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1000 · Cited by 897
Multiple recurrences of major depressive disorder
Solomon, D. A., Keller, M. B., Leon, A. C., Mueller, T. I., Lavori, P. W., Shea, M. T., Coryell, W., Warshaw, M., Turvey, C., Maser, J. D., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.229 · Cited by 835
Residual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791
Reynolds III, C. F., Frank, E., Perel, J. M., Imber, S. D., Cornes, C., Miller, M. D., Mazumdar, S., Houck, P. R., Dew, M. A., Stack, J. A., et al. (1999) · JAMA · doi:10.1001/jama.281.1.39 · Cited by 659
Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Prien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
The Clinical Course of Unipolar Major Depressive Disorders
Judd, L. L. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230015002 · Cited by 460
Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients
Burke, W. J., Gergel, I., & Bose, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0410 · Cited by 350
Self-citationKeller, M. B., & Boland, R. J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00110-3 · Cited by 281
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
The Prophylactic Efficacy of Fluoxetine in Unipolar Depression
Montgomery, S. A., Dufour, H., Brion, S., Gailledreau, J., Laqueille, X., Ferrey, G., Moron, P., Parant-Lucena, N., Singer, L., Danion, J. M., et al. (1988) · British Journal of Psychiatry · doi:10.1192/s0007125000297328 · Cited by 232
Wade, A., Michael Lemming, O., & Bang Hedegaard, K. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200205000-00001 · Cited by 231
NIMH Clinical Research Branch Collaborative Program on the Psychobiology of Depression
Katz, M. M. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780070043004 · Cited by 226
Residual symptoms at remission from depression: Impact on long-term outcome
Kennedy, N., & Paykel, E. S. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(03)00054-5 · Cited by 199
Lader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
(1997) · PubMed · Cited by 149
Frank, E., Kupfer, D. J., Perel, J. M., Cornes, C. L., Mallinger, A. G., Thase, M. E., McEachran, A. B., & Grochocinski, V. J. (1993) · Journal of Affective Disorders · doi:10.1016/0165-0327(93)90001-z · Cited by 140
Prevention of relapse in generalized anxiety disorder by escitalopram treatment
Allgulander, C., Florea, I., & Huusom, A. K. T. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005973 · Cited by 132
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Self-citationIntroduction: treatment of depression in long-term care patients.
Thase, M. E. (1999) · PubMed · Cited by 116
Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115
Bielski, R. J., Bose, A., & Chang, C.-C. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230590932326 · Cited by 109
Self-citationZimmerman, M., Chelminski, I., & Posternak, M. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200401000-00001 · Cited by 105
Hochstrasser, B., Isaksen, P. M., Koponen, H., Lauritzen, L., Mahnert, F. A., Rouillon, F., Wade, A. G., Andersen, M., Pedersen, S. F., De Swart, J. C. G., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.4.304 · Cited by 85
Lépine, J.-P., Caillard, V., Bisserbe, J.-C., Troy, S., Hotton, J.-M., Boyer, P., & For the PREVERS Investigators (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.836 · Cited by 83
Serotonin Reuptake Inhibitor Discontinuation Syndrome: A Hypothetical Definition
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · The Journal of Clinical Psychiatry · Cited by 82
Venlafaxine Versus Placebo in the Preventive Treatment of Recurrent Major Depression
Montgomery, S. A., Entsuah, R., Hackett, D., Kunz, N. R., Rudolph, R. L., & Venlafaxine 335 Study Group (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0307 · Cited by 69
Terra, J.-L., & Montgomery, S. (1998) · PubMed · Cited by 66
Franchini, L., Gasperini, M., Perez, J., Smeraldi, E., & Zanardi, R. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0504 · Cited by 60
Fluoxetine in the Prevention of Depressive Recurrences: A Double-Blind Study
Gilaberte, I., Montejo, A. L., de la Gandara, J., Perez-Sola, V., Bernardo, M., Massana, J., Martin-Santos, R., Santiso, A., Noguera, R., Casais, L., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00009 · Cited by 58
Terra, J. L., & Montgomery, S. A. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803000-00001 · Cited by 51
Hirschfeld, R. M. A. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2000.tb10946.x · Cited by 45
Long-Term Treatment of Major Depressive Disorder With Paroxetine
DUBOFF, E. A. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199312002-00005 · Cited by 23
One-year course of the first vs. multiple episodes of depression—Polish naturalistic study
RYBAKOWSKI, J. K., Nawacka-Pawlaczyk, D., & Kiejna, A. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.06.004 · Cited by 7
Cited by
Citalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Gartlehner, G., Gaynes, B. N., Hansen, R. A., Thieda, P., DeVeaugh-Geiss, A., Krebs, E. E., Moore, C. G., Morgan, L., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00008 · Cited by 237
“…et al., 2002 (235) Acute 8 230 Citalopram, 20–40 – Fair Continuation 16 172 Citalopram, 20–40 – Maintenance 48 60 Citalopram, 20–40 19 (32) NR 61 Placebo 41 (67) Kornstein et al., 2006 (236) Acute 8 131 Citalopram, 20–60 – Fair 129 Fluoxetine, 20–80 128 Paroxetine, 20–50 127 Sertraline,…”
Nelson, J. C., Delucchi, K., & Schneider, L. S. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000308883.64832.ed · Cited by 230
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
“…van den Broek et al. 2006), SSRIs (citalopram (Hochstrasser et al. 2001; Klysner et al. 2002)) (CE A, RG 1), escitalopram (Rapaport et al. 2004; Kornstein et al. 2006)) (CE A, RG 1), fl uoxetine (Gilaberte et al. 2001; Keller et al. 2007)) (CE A, RG 2), fl uvoxamine (Terra and Montgomery 1998)…”
Background
Metadata
- Authors
- Kornstein, S. G., Bose, A., Li, D., Saikali, K. G., & Gandhi, C.
- Affiliations
- Virginia Commonwealth University (US)
- ORCID
- Li, Dayong
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-11-15
- Volume
- 67
- Issue
- 11
- Pages
- 1767-1775
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1977596557
- Cited by
- 60
- References
- 39
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 5 · 2015: 5 · 2014: 2 · 2013: 1 · 2012: 3
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- escitalopram, recurrent major depressive disorder, depression recurrence prevention, selective serotonin reuptake inhibitors, continuation treatment, treatment response, drug tolerability
- MeSH terms
- Adult, Aged, Aged, 80 and over, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Citalopram, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.